SCHEMBL3974924

SCHEMBL3974924

CSc1ccc(C(=O)C=Cc2cc(C)c(OCC(=O)O)c(C)c2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.67
PPARD Q03181 1/20 0.67
PPARA Q07869 1/20 0.67
LMNA P02545 3/20 0.55
MAPT P10636 3/20 0.55
KDM4E B2RXH2 1/20 0.55
POLB P06746 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
MEN1 O00255 2/20 0.52
ALDH1A1 P00352 2/20 0.52
RAB9A P51151 2/20 0.52
KMT2A Q03164 2/20 0.52
GAA P10253 1/20 0.52
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
NPC1 O15118 1/20 0.51
NFKB1 P19838 1/20 0.51
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974921 1.00 PPARG (0.67) PPARGPPARDPPARALMNAMAPT
SCHEMBL28612717 0.86 PPARG (0.62) PPARGPPARDPPARALMNAMAPT
SCHEMBL28612719 0.86 PPARG (0.62) PPARGPPARDPPARALMNAMAPT
SCHEMBL28608357 0.86 PPARG (0.70) PPARGPPARDPPARALMNAMAPT
SCHEMBL28608418 0.86 PPARG (0.64) PPARGPPARDPPARALMNAMAPT
SCHEMBL13764712 0.85 PPARG (0.64) PPARGPPARDPPARALMNAMAPT
SCHEMBL3969830 0.85 MAPT (0.55) PPARGPPARDPPARALMNAMAPT
SCHEMBL3969826 0.85 MAPT (0.55) PPARGPPARDPPARALMNAMAPT
SCHEMBL20932824 0.81 PPARG (0.80) PPARGPPARDPPARALMNAMAPT
SCHEMBL14523108 0.81 PPARG (0.66) PPARGPPARDPPARALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9221751-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2015-12-29 US claimed
US-20150051145-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2015-02-19 US claimed
US-7566737-B2 Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2009-07-28 US claimed
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2007-02-08 US claimed
CN-113230240-B 1,3-diphenylprop-2-en-1-one derivative and application thereof 广州医科大学 2022-12-27 CN disclosed
CN-113230240-A 1, 3-diphenylprop-2-en-1-one derivative and application thereof 广州医科大学 2021-08-10 CN disclosed
US-20200384105-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2020-12-10 US disclosed
US-10722575-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2020-07-28 US disclosed
US-20190275146-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2019-09-12 US disclosed
US-10350181-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2019-07-16 US disclosed
US-20180280328-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2018-10-04 US disclosed
US-10022343-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2018-07-17 US disclosed
US-9782373-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2017-10-10 US disclosed
US-20170128399-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2017-05-11 US disclosed
US-9585853-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2017-03-07 US disclosed
US-20160051501-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2016-02-25 US disclosed
US-9221751-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2015-12-29 US disclosed
US-20150051145-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2015-02-19 US disclosed
US-7566737-B2 Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2009-07-28 US disclosed
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170128399-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients PSEN1, BACE1, PSEN2 PPARG 17/4885PPARD 39/4885PPARA 69/4885
US-20160051501-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885
US-20150051145-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885
US-20190275146-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885
US-20180280328-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885
US-20200384105-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885
US-10722575-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885
US-10350181-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885
US-10022343-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.